Author of

• 25902

  +

  MA13 - Interventional Pulmonology (ID 914)

  • Event: WCLC 2018
  • Type: Mini Oral Abstract Session
  • Track: Interventional Diagnostics/Pulmonology
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 10:30 - 12:00, Room 206 AC

  • 26016

    +

    MA13.11 - Photodynamic Therapy for Peripheral-Type Lung Cancer in a Multi-Center Clinical Trial (ID 13691)

    11:40 - 11:45  |  Presenting Author(s): Jitsuo Usuda
    • Abstract
    • Presentation
    • Slides

    Background
    

    Photodynanic therapy (PDT), is a treatment modality for many cancers, and uses a tumor-specific photosensitizer and laser irradiation. Recently, we have developed a new minimally invasive laser device using a 1.0 mm in diameter composite-type optical fiberscope (COF), which could transmit laser energy and images for observation in parallel.In this study, we aimed to develop a new endobronchial treatment for peripheral cancer using PDT and a COF, and we evaluated the feasibility of PDT using COF for peripheral lung cancer.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    This phase I study enrolled 3 patients with peripheral lung cancers (primary tumor< 20 mm, stage IA), which were definitively diagnosed by bronchoscopic modalities such as EBUS-GS and brocnhoscopic navigation system. We conducted irradiation using a diode laser (664 nm) and a COF 4 hours after the administration of NPe6 40 mg/m². We evaluated the tumor lesions using EBUS, and then we introduced the COF into the peripheral lung cancer, and irradiated of red light 664 nm (120 mW, 50 J/cm² or 100J/cm2).　

    4c3880bb027f159e801041b1021e88e8 Result
    

    We performed PDT for 3 patients with c-stage IA peripheral lung cancer, using a laser dose (120mW, 50J/cm2), and confirmed the feasibility of the dose. We escalated the laser dose and performed 4 patients using a laser dose (120mW, 100J/cm2).

    Seven patients met our criteria, and 5 cases were adenocarcinoma and 2 case squamous cell carcinoma. We were able to observe the cancer lesions at the peripheral lung by the COF, and feasibly irradiated. Two weeks and 3 months after NPe6-PDT, complications such as pneumonia and pneumothorax were not found, but one mildly found light skin-photosensitivity. Six months later, we found CR in 3 cases and SD in 4 cases.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    The 1.0 mm COF was a very useful device of NPe6-PDT for peripheral lung cancers, and PDT was a feasible and non-invasive treatment for a peripheral type early lung cancer. In the future, for non-invasive adenocarcinoma such as AIS, NPe6-PDT will become a treatment modality.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

• 25940

  +

  P2.03 - Biology (Not CME Accredited Session) (ID 952)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26971

    +

    P2.03-33 - Anti-Aging Gene, Klotho is a Predictive Factor of Pemetrexed for Lung Cancer Treatment (ID 12714)

    16:45 - 18:00  |  Author(s): Jitsuo Usuda
    • Abstract
    • Slides

    Background
    

    Adjuvant chemotherapy of lung cancer including cisplatin is recommended for patients with lung cancer p-stage IB-IIIA, who were received surgical resection completely. In order to improve the prognosis of the patients with lung cancers, we need to find a new predictive factor for anti-cancer agents and establish a new adjuvant chemotherapy.

    We reported that anti-aging gene Klotho expression was a prognostic factor for small cell lung cancer and LCNEC so far. In this study, we evaluated that the expression of Klotho was a prognostic factor and predictive factor for lung cancer treatment.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We established a cell line, A549/Klotho, which stably overexpress Klotho. Next, we checked expression of Epithelial-Mesenchymal Transition related protein such as N-cadherin, E-cadherin, Snail, Vimentin, etc, by Western blot analysis. Finally, We examined the sensitivity test for various anticancer agents including pemetrexed, CDDP, paclitaxel, gefitinib, etc, using A549 cells and A549/Klotho cells.

    4c3880bb027f159e801041b1021e88e8 Result
    

    In Western blot analysis, no expression of N-cadherin was observed. This result indicated that overexpressing Klotho inhibit the expression of N-cadherin, and suggest that Klotho can regulate the EMT. Secondly, we performed sensitivity test by MTT assay. A549/Klotho cells were more sensitive seven times against pemetrexed compared to A549 cells (IC50; 0.1 micro M). There is no difference of sensitivity between A549/Klotho cells and A549 cells against molecular target drugs such as gefitinib.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    From these result, we conclude that overexpression of Klotho may regulate the sensitivity against pemetrexed through the inhibition of N-cadherin. In the future, we may establish a new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.